OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Proprietary cell lines offer opportunities for achieving high AAV titers.
In the ATMP space, CGTs are hitting their stride with unprecedented approvals in the past year alone.
October 18, 2024
Cell and gene therapy experts Fabian Gerlinghaus, Dr. Claudia Zylberberg, and Benjamin McLeod weigh in on hot topics in CGT.
Webinar Date/Time: Thu, Nov 7, 2024 11:00 AM EDT
October 17, 2024
Through the collaboration, Merck will use Mestag’s proprietary RAFT platform to investigate the pathogenic role that fibroblasts play in inflammatory diseases.
The establishment of this new center aims to expedite R&D processes, reduce costs, and potentially lead to accelerated discovery of new candidate therapies.
October 11, 2024
At CPHI Milan, Nicolas Camper, senior director—Bioconjugation Chemistry, Abzena, spoke about new developments in ADC technologies, including the role of complex chemistries.
October 10, 2024
Solving the challenge of better-stabilized temperature-sensitive biomolecules hinges on innovative formulation strategies.
At this year's CPHI Milan, Camille Dumont, PhD, manager, customer applications, Lonza, discussed current industry trends that are impacting oral solid dose formulation work.
October 09, 2024
At CPHI Milan, Stacey Treichler, senior director of global marketing and strategy, Purolite, an Ecolab company, spoke about current trends in the biopharma industry and innovations in purification resins .